Tag Archives: ASCO

Caris-Sponsors-at-ASCO

ADVOCATE SPOTLIGHT: Debra’s Thoughts on ASCO

ADVOCATE SPOTLIGHT: Debra’s Thoughts on ASCO

by Debra Merritt, advocate MY JOURNEY WITH CANCER On November 14, 2008 my journey with cancer began with my husband Cliff’s stage IV colon cancer diagnosis. We had lived an amazing life, married as students in college at the age of 20, and were just four days away from our 30th anniversary and six days away from his 51st birthday. We had two beautiful daughters in college. Cliff began to experience severe abdominal cramps which led to a colonoscopy and to the diagnosis a few days later. As soon as Cliff was diagnosed, he made it his mission to encourage everyone we knew to get a colonoscopy. He made sure that they were informed about the importance

July 2014 Webinar – The Latest News About CRC Research & Treatment

Learn the latest findings from the American Society of Clinical Oncology (ASCO) conference in May. The latest studies, treatments and developments and how they impact colorectal cancer patients were discussed. PRESENTED BY: Cathy Eng, M.D. Associate Professor, Department of Gastrointestinal (GI) Medical OncologyDr. Cathy Eng is Associate Professor in the Department of Gastrointestinal (GI) Medical Oncology at The University of Texas M. D. Anderson Cancer Center. Dr. Eng received her medical degree from Hahnemann University School of Medicine in Philadelphia, PA, followed by an internship and residency at Rush-Presbyterian St. Luke’s Medical Center in Chicago, IL. She went on to complete a fellowship in Hematology/Oncology at University of Chicago Medical Center. Dr. Eng is board certified in

ASCO-booths

Andi’s Highlights on ASCO 2014

by Andi Dwyer, Director of Health Promotion, Fight Colorectal Cancer Working in the cancer prevention and survivorship field for nearly ten years, I was elated to attend my first ASCO.  However, nothing prepared me for the 35,000 people from throughout the world, gathered to unveil the latest in ‘all things’ cancer.  I came in with a notion this was a research conference; I discovered, it was so much more. Policy, advocacy, pharmaceutical, basic research and clinical/medical science from the entire planet, collided into a single city for a solid four days.  It was intense and complete with opportunity and challenge but none-the-less, a guide for this year and beyond. ASCO info about Biomarkers

You don’t have to be a scientist to get involved in research

Remember the feeling of being a young freshman student walking the halls lined with senior lockers? Sweaty palms. Knocking knees. It was intimidating to be surrounded by upper classman. As a cancer survivor, sometimes the research process can feel similar to the “good” ole’ days of high school. Especially if you don’t love chemistry. But as Florence, a survivor and advocate can attest, if you give it a little time — research can be for ANYONE. Although it may not come easy for you at first, when you slow down and take small steps, you too will begin to see that research isn’t always as complex or difficult as it

Stage II Colon Cancer – Chemo or No Chemo?

A brief in a running series from 2013 ASCO® conference: Prognostic Tests – to use or not use . . .  or rather  … To treat or not to treat? New studies for stage II colon cancer patients contemplating chemotherapy . by: Nancy Roach One of the toughest decisions for patients with stage II colon cancer is whether or not to receive chemotherapy after surgery. In a perfect world, there would be a test that could predict whether or not the cancer will reoccur and research to predict which treatment will help each patient at risk. For now, each patient’s decision is based on a wide variety of factors. Tests to

Experts Issue Practice-Changing Advice: Stop giving calcium/magnesium for oxaliplatin-caused neuropathy

For patients getting the common FOLFOX chemotherapy for colorectal cancer, many oncologists add intravenous calcium and magnesium, hoping to decrease the neuropathy (nerve damage) associated with oxaliplatin-based drugs. But this week, experts at the 2013 ASCO meeting (American Society of Clinical Oncology), announced strong evidence that the calcium/magnesium does no good in either preventing or decreasing neuropathy—and it should no longer be part of routine treatment. Neuropathy affects cancer treatment Oxaliplatin-based chemotherapy (e.g. FOLFOX, with Eloxatin®) is one of the most commonly used drugs for people having high-risk stage II, or stages III or IV colorectal cancer. But far too often after patients have had many doses of FOLFOX over

Clinical Conundrum: When, how to treat colorectal cancer in the elderly

Even as scientists plumb deep into cells and molecules to understand cancer, there are many immediate and “real-life” questions that researchers and clinicians are discussing at the 2013 annual ASCO meeting (American Society of Clinical Oncology). One of the biggest puzzles for colorectal cancer is how to best treat the elderly, especially those with stages II or III (non-metastatic) cancer. It’s a huge question: today, 40 percent of colorectal cancer patients are elderly, and by the year 2030, more than 70 percent of non-inherited colorectal cancer will be among those 65 or older. Currently, 70 years old is the median age at diagnosis, with fully 40 percent of diagnoses made

“Hope and Progress” takes an army – 30,000 of them!

As you may already have read, team members of Fight Colorectal Cancer which includes Staff, Board, Grassroots Action Committee (GAC) along with our Medical Advisory Board (MAB) have been in full swing at the Chicago 2013 Gastrointestinal Cancers Symposium. The American Society of Clinical Oncology® has been on top of their game with the distribution of material which we can barely keep up with! You can find a treasure chest of details here. This is by far the world’s largest organization of cancer specialists in one place at any time during the year. They are gathered to listen to scientific researchers present their latest findings, clinical specialists (oncologists, surgeons, radiologists,

Patient Involvement in Decision-Making: A long way to go

This week brings some excellent reading about why and how to educate patients so they can help make better decisions about their own care. What happens when patients get to read their own medical records? The Oct. 2nd  Annals of Internal Medicine published two editorials and results of a quasi-experimental trial of 100 primary care doctors who voluntarily provided 13,500 patient volunteers with access to their doctors’ notes for a year. To read details, read further, but some results in brief : patients loved being able to read their visit report, and 75% said they were more likely to take medicines as directed; doctors didn’t see increased patient anxiety, visits, or time demands. Meanwhile,

Choosing Wisely: What CancerTests and Treatments Do You Really Need?

Oncologists have joined eight other physician specialty organizations in the Choosing Wisely® campaign with a list of the Top Five Cancer-Related Tests, Procedures, and Treatments That Many Patients Do Not Need. Choosing Wisely asked each of the specialist groups to come up with a list of five things doctors and patients should question in order to improve evidence-based care, avoid tests or treatments that don’t help, and reduce the burden of health care costs. Here are the Top Five lists from the other groups. The American Society of Clinical Oncology  built the Top Five List for Oncology, based on work that ASCO’s Cost of Care Task Force has been doing

Top